Use of a Recombinant Cysteine Proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of Canine Visceral Leishmaniasis

Autor(es)

Lima Ferreira, Josie Haydee ^{[1, 2]} ; Silva, Lucilene dos Santos ^[3] ; Longo-Maugeri, Ieda Maria ^[1] ; Katz, Simone ^[1] ; Barbieri, Clara Lucia ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, Sao Paulo - Brazil

^[2] Univ Fed Piaui, Ctr Ciencias Saude, Dept Parasitol & Microbiol, Teresina, Piaui - Brazil

^[3] Univ Fed Piaui, Ctr Ciencias Agr, Teresina, Piaui - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PLoS Neglected Tropical Diseases; v. 8, n. 3 MAR 2014.
• Citações Web of Science: 8

Resumo

Background: A recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi (rLdccys1) was previously shown to induce protective immune responses against murine and canine visceral leishmaniasis. These findings encouraged us to use rLdccys1 in the immunotherapy of naturally infected dogs from Teresina, Piaui, a region of high incidence of visceral leishmaniasis in Brazil. Methodology/Principal Findings: Thirty naturally infected mongrel dogs displaying clinical signs of visceral leishmaniasis were randomly divided in three groups: one group received three doses of rLdccys1 in combination with the adjuvant Propionibacterium acnes at one month interval between each dose; a second group received three doses of P. acnes alone; a third group received saline. The main findings were: 1) dogs that received rLdccys1 with P. acnes did not display increase of the following clinical signs: weight loss, alopecia, onychogryphosis, cachexia, anorexia, apathy, skin lesions, hyperkeratosis, ocular secretion, and enlarged lymph nodes; they also exhibited a significant reduction in the spleen parasite load in comparison to the control dogs; 2) rLdccys1-treated dogs exhibited a significant delayed type cutaneous hypersensitivity elicited by the recombinant antigen, as well as high IgG2 serum titers and low IgG1 serum titers; sera from rLdccys1-treated dogs also contained high IFN-gamma and low IL-10 concentrations; 3) control dogs exhibited all of the clinical signs of visceral leishmaniasis and had low serum IgG2 and IFN-gamma levels and high concentrations of IgG1 and IL-10; 4) all of the dogs treated with rLdccys1 were alive 12 months after treatment, whereas dogs which received either saline or P. acnes alone died within 3 to 7 months. Conclusions/Significance: These findings illustrate the potential use of rLdccys1 as an additional tool for the immunotherapy of canine visceral leishmaniasis and support further studies designed to improve the efficacy of this recombinant antigen for the treatment of this neglected disease. (AU)

• Processo FAPESP: 07/55465-7 - A cisteina proteinase recombinante de leishmania (leishmania) chagasi (rldccys1): alvo para diagnostico e imunidade protetora de caes em area endemica de leishmaniose visceral, teresina/pi.
• Beneficiário: Clara Lúcia Barbiéri Mestriner
• Modalidade de apoio: Auxílio à Pesquisa - Regular